Starling Oncology, Inc.(STLN)

Medical - Care Facilities · Cerritos, CA

$6.58+0.28 (+4.44%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

Starling Oncology (STLN) EV/EBIT: History & Chart | TGMCharts

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T22:28:43.084Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:28:43.084Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 657,887,699
Total debt · period ending 2026-06-30: 104,476,000
Cash · period ending 2026-06-30: 41,094,000
TTM operating income · period ending 2026-06-30: -26,090,000

FMP input reference: ad03cc2eaddb42082332b148aee8d6851fa015397d59a0785f41cacae5aa3ea4

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

STLN EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

STLN Competitors' EV/EBIT Ratio

STLN

Starling Oncology, Inc.

Current

Market Cap

$657.89M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FDMT

4D Molecular Therapeutics, Inc.

vs STLN

Market Cap

$656.59M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ANNX

Annexon, Inc.

vs STLN

Market Cap

$660.29M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HELP

Helus Pharma Inc.

vs STLN

Market Cap

$666.95M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MDXG

MiMedx Group, Inc.

vs STLN

Market Cap

$673.41M

EV/EBIT Ratio

61.60x

TTM Avg

21.67x

3Y Avg

25.85x

5Y Avg

35.25x

AURA

Aura Biosciences, Inc.

vs STLN

Market Cap

$638.20M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VSTM

Verastem, Inc.

vs STLN

Market Cap

$681.02M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SLDB

Solid Biosciences Inc.

vs STLN

Market Cap

$681.27M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ZVRA

Zevra Therapeutics, Inc.

vs STLN

Market Cap

$634.30M

EV/EBIT Ratio

12.55x

TTM Avg

14.57x

3Y Avg

14.57x

5Y Avg

18.55x

PRME

Prime Medicine, Inc.

vs STLN

Market Cap

$632.16M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Starling Oncology, Inc. (STLN)	$657.89M	N/A	N/A	N/A	N/A
4D Molecular Therapeutics, Inc. (FDMT)vs ›	$656.59M	N/A	N/A	N/A	N/A
Annexon, Inc. (ANNX)vs ›	$660.29M	N/A	N/A	N/A	N/A
Helus Pharma Inc. (HELP)vs ›	$666.95M	N/A	N/A	N/A	N/A
MiMedx Group, Inc. (MDXG)vs ›	$673.41M	61.60x	21.67x	25.85x	35.25x
Aura Biosciences, Inc. (AURA)vs ›	$638.20M	N/A	N/A	N/A	N/A
Verastem, Inc. (VSTM)vs ›	$681.02M	N/A	N/A	N/A	N/A
Solid Biosciences Inc. (SLDB)vs ›	$681.27M	N/A	N/A	N/A	N/A
Zevra Therapeutics, Inc. (ZVRA)vs ›	$634.30M	12.55x	14.57x	14.57x	18.55x
Prime Medicine, Inc. (PRME)vs ›	$632.16M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

STLN EV/EBIT Ratio Metrics

STLN Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics